Remondo, C., Tagliaferri, P., Rotundo, M.S., Tassone, P., Del Vecchio, M.T., Migali, C., et al. (2009). Immune-regulatory (FoxP3+)-T-cell tumor infiltration status is predictive of benefit from chemo-immunotherapy with gemcitabine, oxaliplatin, 5FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients. EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, 7(2), 146-147 [10.1016/S1359-6349(09)70499-9].

Immune-regulatory (FoxP3+)-T-cell tumor infiltration status is predictive of benefit from chemo-immunotherapy with gemcitabine, oxaliplatin, 5FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients

Francini G;
2009-01-01

2009
Remondo, C., Tagliaferri, P., Rotundo, M.S., Tassone, P., Del Vecchio, M.T., Migali, C., et al. (2009). Immune-regulatory (FoxP3+)-T-cell tumor infiltration status is predictive of benefit from chemo-immunotherapy with gemcitabine, oxaliplatin, 5FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients. EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, 7(2), 146-147 [10.1016/S1359-6349(09)70499-9].
File in questo prodotto:
File Dimensione Formato  
Immune-regulatory FoxP3+-abs-2009.pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 69.26 kB
Formato Adobe PDF
69.26 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/35508